araag2/HINT huggingface dataset:
Clinical trial NCT02174276 (phase 2, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: tenofovir disoproxil fumarate
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form, which
             must be obtained prior to initiation of study

          -  Documented evidence of chronic hepatitis B virus (HBV) infection, for example,
             hepatitis B surface antigen (HBsAg) positive for more than 6 months

          -  Screening HBV DNA ≥ 2000 IU/mL

          -  A negative serum pregnancy test is required for females (unless surgically sterile or
             > 2 years post-menopausal)

        Key Exclusion Criteria:

          -  Cirrhosis

          -  Inadequate liver function

          -  Co-infection with hepatitis C virus (HCV), HIV or hepatitis D virus (HDV)

          -  Received antiviral treatment for HBV within 3 months of screening

          -  Evidence of hepatocellular carcinoma (eg, as evidenced by recent imaging)

          -  Significant cardiovascular, pulmonary, or neurological disease

          -  Women who are pregnant or may wish to become pregnant during the course of the study

          -  Received solid organ or bone marrow transplant

          -  Received prolonged therapy with immunomodulators (eg, corticosteroids) or biologics
             (eg, monoclonal antibody, interferon) within 3 months of screening

          -  Use of investigational agents within 3 months of screening

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with individual's compliance

          -  Receipt of immunoglobulin or other blood products within 3 months prior to enrollment

          -  History of demyelinating disease (Guillain-Barre), Bell's Palsy, Crohn's disease,
             Ulcerative colitis, or autoimmune disease

          -  Documented history of yeast allergy

          -  Known hypersensitivity to study drugs, metabolites or formulation excipients

          -  Malignancy within 5 years prior to screening, with the exception of specific cancers
             that are cured by surgical resection (basal cell skin cancer, etc). Individuals under
             evaluation for possible malignancy are not eligible

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02175121 (phase 2, status: completed)
Conditions: diabetes mellitus, type ii
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: placebo, pf-06291874, pf-06291874, pf-06291874, pf-06291874
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male subjects and non-childbearing potential female subjects between the ages of 18
             and 70 years old.

          -  Body Mass Index of 18.0 to 45.4 kg/m2; and a total body weight of >50 kg

          -  HbA1c value at the screening visit meeting once of the following criteria:

               -  Currently taking acceptable oral antiglycemic drug therapy within 6.5 to 9.5%

               -  Not currently taking any oral antiglycemic drug therapy within 7 to 10.5%

          -  Fasting plasma glucose concentrations<270mg/dL at the screening and run-in visit,
             confirmed by a single repeat, if deemed necessary.

          -  Subjects must be willing and able to perform self-tests of blood glucose at least 4
             times per day, and maintain a diary for the duration of participation in the study;
             and therefore, subjects must be literate.

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus or secondary forms of diabetes

          -  One or more self-reported hypoglycemic episodes of sever intensity within 3 months of
             screening; or 2 or more self-reported hypoglycemic episodes of severe intensity within
             the previous 6 months.

          -  History of myocardial infarction, unstable angina, arterial revascularization, stroke,
             New York Heart Association Functional Class II-IV heart failure, or transient ischemic
             attach within 6 months of screening.

          -  History or evidence of diabetic complications with significant end organ damage, such
             as

               -  Proliferative retinopathy and/or macular edema;

               -  Diabetic neuropathy complicated by neuropathic ulcers;

          -  Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure
             >100 mm Hg after at least a 5 minute seated rest. If the blood pressure exceeds this
             limit, the blood pressure may be repeated 2 more times following approximately 2
             minutes of rest between measurements and the median of the 3 values should be used to
             determine subject eligibility;

          -  Male subjects with partners currently pregnant; or male subjects capable of conceiving
             children who are unwilling or unable to use a highly effective method of contraception
             as outlined in this protocol for the duration of the study and for at least 28 days
             after the last dose of investigational product.
Clinical trial NCT02175966 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: dcv/asv/bms-791325, ribavirin, sofosbuvir, peginterferon α-2a
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Males and Females ≥18 years of age, inclusive

          -  Chronic HCV infection Genotype 1 only

          -  Non-cirrhotic

          -  Treatment naive subjects with no previous exposure to an Interferon formulation (ie,
             IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease,
             polymerase inhibitor, etc.)

        Exclusion Criteria:

          -  HCV Genotype other than Genotype 1

          -  Documented or suspected hepatocellular carcinoma

          -  Evidence of decompensated liver disease

          -  Contraindication(s) to Peg/RBV therapy
Clinical trial NCT02177786 (phase 2, status: completed)
Conditions: diabetic kidney disease
ICD codes: E10.22, E11.22, E13.22, E08.22, E09.22
Drugs: selonsertib, placebo to match selonsertib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Adult male or females with prior diagnosis of Diabetic Kidney Disease

          -  Type 2 diabetes mellitus diagnosis for at least 6 months

          -  eGFR (MDRD) at screening ≥ 15 mL/min/1.73m^2 to < 60 mL/min/1.73m^2

          -  Urine albumin to creatinine ratio (UACR) as follows:

               -  Stage/Stratum 3a: eGFR range 45 to < 60 mL/min; UACR ≥ 600 mg/g

               -  Stage/Stratum 3b: eGFR range 30 to < 45 mL/min; UACR ≥ 300 mg/g

               -  Stage/Stratum 4: eGFR range 15 to < 30 mL/min; UACR ≥ 150 mg/g

          -  Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor
             blockers (ARB) at a minimum dose deemed appropriate for the individual by the
             investigator and be at a stable dose for the last three months

               -  Individuals not on ACEi/ARB may be screened if there is documented intolerance to
                  ACE inhibitor and/or ARB

        Key Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  HbA1c > 9.5%

          -  Non-diabetic kidney disease

          -  UACR > 5000 mg/g on any measurement during screening

          -  End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status
             post renal transplantation) or anticipated to occur within the treatment period

          -  Unstable cardiovascular disease

          -  Pregnant or lactating females

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02178098 (phase 2, status: completed)
Conditions: hypercholesterolemia, hypertension
ICD codes: E78.01, E78.00, Z83.42, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: etc-1002, placebo
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg

          -  or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg

          -  Fasting LDL-C between 100 and 220 mg/dL

          -  Fasting triglycerides less than 400 mg/dL

          -  Body mass index (BMI) between 18 and 45 kg/m2

        Exclusion Criteria:

          -  Known or suspected secondary hypertension or history of malignant hypertension

          -  Taking more than two anti-hypertension medications at the first visit

          -  History or current clinically significant cardiovascular disease

          -  History or current type 1 diabetes or type 2 diabetes
Clinical trial NCT02180464 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: las41004, control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria (main):

          -  mild to moderate stable chronic plaque-type psoriasis with at least two symmetrical
             lesions with a treatment area of 20 - 300 cm² and a TSS of ≥ 6;

               -  female volunteers of childbearing potential* must agree to use appropriate and
                  reliable methods of contraception

               -  written informed consent obtained.

        Exclusion Criteria (main):

          -  severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,

          -  treatment with any locally acting medications which might counter or influence the
             trial aim within 2 weeks preceding the treatment phase of the trial and during the
             trial;

          -  treatment with any systemic medications which might counter or influence the trial aim
             or phototherapy/PUVA within 4 weeks preceding the treatment phase of the trial and
             during the trial;

          -  treatment with vitamin A supplements;

          -  treatment with any biologics within 3 months preceding the treatment phase of the
             trial and during the trial, or in the case of ustekinumab, within 6 months;

          -  treatment with any immunosuppressive medication within 6 months preceding the
             treatment phase of the trial and during the trial;

          -  known allergic reactions, irritations or hypersensitivity to the active ingredients

          -  contraindications according to summary of product characteristics (SmPC) of the active
             comparator: - pregnancy or nursing;
Clinical trial NCT02181738 (phase 2, status: active, not recruiting)
Conditions: hodgkin disease
ICD codes: C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70
Drugs: nivolumab, doxorubicin, vinblastine, dacarbazine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, N1C=CN=C1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Must have received prior high-dose conditioning chemotherapy followed by autologous
             stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C -
             enrollment closed)

          -  Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab
             vedotin treatment (cohort A, B & C - enrollment closed)

          -  Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

        Exclusion Criteria:

          -  Known central nervous system lymphoma

          -  Participants with nodular lymphocyte-predominant Hodgkin Lymphoma

          -  Prior allogeneic stem cell transplantation (SCT)

          -  Chest radiation ≤ 24 weeks prior to first dose

          -  Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen
Clinical trial NCT02185768 (phase 2, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: idarubicin
SMILES: [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  - Histologically diagnosed HCC or HCC diagnosed according to the EASL criteria

          -  Measurable targets according to the mRECIST v1.1 criterion

          -  Preserved liver function (in case of Child-Pugh A or B7 cirrhosis)

          -  Tumour not subject to interventive care (liver transplant, surgical resection or
             percutaneous destruction)

          -  BCLC A/B without portal or extra-hepatic invasion

          -  No prior treatment by chemotherapy, radiotherapy or transarterial embolisation (with
             or without chemotherapy)

          -  Age ≥ 18 years

          -  WHO 0 or 1

          -  Laboratory test: platelets ≥ 50,000 mm3, N ≥ 1,000/mm3, creatininaemia ≤ 150 µmol/L,
             PT ≥ 50%

          -  No heart failure (isotope or ultrasound VEF > 50%)

        Exclusion Criteria:

          -  - Advanced tumour (vascular or extra-hepatic invasion including brain metastasis or
             diffuse HCC with liver invasion > 50%)

          -  History of other type of cancer except cancer known to be in remission for more than 5
             years (in this case, HCC histological proof is required), or basal-cell carcinoma or
             in situ cervix uteri cancer properly treated with curative treatment

          -  Advanced liver disease (Child B8, B9 and C, bilirubinaemia > 3 mg/dL, SGOT and SGPT >
             5 x ULN or 250 U/L)

          -  Previous treatment by idarubicin and/or doxorubicin

          -  Idarubicin contraindications (cardiopathy with myocardial failure, serious kidney or
             liver failure, yellow fever vaccine)

          -  Concurrent disease or uncontrolled severe clinical condition

          -  Uncontrolled severe infection

          -  Patient requiring long-term anticoagulant treatment

          -  Thrombosis of the portal vein or a 3-segment region or more

          -  Hepatofugal portal venous flow

          -  Presence of serious atheromatosis

          -  Presence of collateral vascular ways potentially affecting the normal regions during
             embolisation

          -  Presence of arthritis of the hepatic artery branches to be treated

          -  Presence of arterioportal or arterial subhepatic fistula that cannot be embolised by
             coils

          -  Pregnancy or breastfeeding

          -  Absence of effective contraception (for men and women of childbearing age)

          -  Patient who cannot be regularly monitored on account of psychological, social, family-
             or geography-related reasons

          -  Concomitant participation of a patient in another study
Clinical trial NCT02186119 (phase 2, status: completed)
Conditions: macular edema
ICD codes: H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120
Drugs: abicipar pegol, ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus (Type 1 or 2)

          -  Decreased vision due to diabetic macular edema in at least 1 eye

          -  Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better
             in the fellow eye

        Exclusion Criteria:

          -  Stroke or heart attack within the past 3 months

          -  History of vitrectomy, macular surgery, or glaucoma surgery in the study eye

          -  Cataract or refractive surgery in the study eye within the last 3 months

          -  Laser photocoagulation of the study eye within the last 3 months
Clinical trial NCT02187302 (phase 2, status: completed)
Conditions: metastatic renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: crlx101, bevacizumab, standard of care (investigator choice)
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Must have histologically confirmed renal cell carcinoma of any pathologic subtype.

          -  Must have unresectable metastatic disease, and have tumor(s) present that is (are)
             evaluable by the RECIST, v1.1; may have spinal-associated metastases but must have
             concluded dexamethasone therapy and be evaluated by the Investigator to have stable
             CNS disease.

          -  Must have received 2 or 3 prior lines of conventional molecularly targeted therapy

          -  Must have full recovery from any toxicities from prior therapy CTCAE Grade 1 or less
             with the exception of Grade 2 alopecia) prior to randomization.

          -  ECOG performance status 0 or 1.

          -  Age 18 years and older.

          -  Life expectancy of at least 3 months.

          -  Must have normal organ and marrow function reported within 14 days prior to
             randomization

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Able to comply with study visit schedule and assessments.

        Exclusion Criteria:

          -  Any conventional molecularly targeted therapy within 2 weeks or, chemotherapy or
             radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study.

          -  Failure to recover to grade 1 or less all prior adverse events.

          -  Any major surgery within 4 weeks of study randomization.

          -  Any prior treatment with topoisomerase I therapy.

          -  Prior treatment with any drugs or therapies that will be administered during the
             course of this trial including CRLX101, any topoisomerase 1 inhibitor, bevacizumab or
             the conventional molecularly targeted agent intended for use as standard of care
             treatment.

          -  Patients receiving any other current investigational therapeutic agent.

          -  Other active malignancies

          -  Patients with brain metastasis treated or untreated, or other CNS disease

          -  Any clinically significant cardiac disease defined as NYHA class III or IV.

          -  Uncontrolled hypertension

          -  Uncontrolled concurrent illness

          -  History of non-healing wounds or ulcers.

          -  Pregnancy, or inadequate contraception for men or women of childbearing age, or
             lactating / breast-feeding

          -  Patients with known HIV or with solid organ transplant
Clinical trial NCT02188160 (phase 2, status: completed)
Conditions: dry eye syndromes, keratoconjunctivitis sicca
ICD codes: H04.121, H04.122, H04.123, H04.129, H16.223, H16.221, H16.222, H16.229
Drugs: kpi-121, placebo
SMILES: [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        • Have a documented clinical diagnosis of dry eye disease in both eyes

        Exclusion Criteria:

          -  Known hypersensitivity/contraindication to study product(s) or components.

          -  History of glaucoma, IOP >21 mmHg at the screening or randomization visits, or being
             treated for glaucoma in either eye.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance;
             severe/serious systemic disease or uncontrolled medical condition that in judgment of
             Investigator could confound study assessments or limit compliance; or have been
             exposed to an investigational drug within the 30 days prior to screening.

          -  In the opinion of Investigator or study coordinator, be unwilling or unable to comply
             with study protocol or unable to successfully instill eye drops.
Clinical trial NCT02189577 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: chf 5259, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults (40 ≤ age ≤ 80 years) with a diagnosis of COPD

          -  Current smokers or ex-smokers

          -  A post-bronchodilator FEV1 < 60% of the predicted normal value and a
             post-bronchodilator FEV1/FVC < 0.7

          -  Positive response to the reversibility test at screening defined as change in FEV1 ≥
             5%.

          -  BDI score ≤ 10

          -  Patients free of exacerbations for at least 1 month

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of asthma

          -  Patients treated for exacerbations in the 4 weeks prior to screening visit

          -  Patients treated with long-acting antihistamines unless taken at stable regimen at
             least 2 months prior to screening and to be maintained constant during the study or if
             taken as PRN

          -  Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic
             hypoxemia

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
Clinical trial NCT02190838 (phase 2, status: terminated)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: metformin, melatonin, dacarbazine
SMILES: CSCC[C@H](N)C(O)=O, COC1=CC2=C(NC=C2CCNC(C)=O)C=C1, N1C=CN=C1
Reason stopped: 
    preliminary terminated due to inefficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age >18.

          -  Obtained Inform Consent

          -  Morphologically confirmed disseminated Stage IV melanoma

          -  Eastern Collaborative Oncology Group Performance Status Scale 0 - 2.

          -  Expected survival >3 month

        Exclusion Criteria:

          -  Evidence of active brain lesions (brain lesions after stereotaxic ray therapy allowed)

          -  Evidence of liver and bone marrow clinically meaningful disfunction

          -  Severe uncontrolled concomitant conditions and diseases

          -  Pregnancy or lactation

          -  Systemic therapy for disseminated melanoma

          -  Second malignancy

          -  Diabetes mellitus requiring drug therapy

          -  Any condition preventing study participation by investigator opinion